Comparar compuestos

GHK-Cu

Start

1 mg

Range

1–2 mg

Frequency

Once daily

Cycle

4–8 weeks

Vials

50 / 100 mg

Tesamorelin

Viales

10 / 20 mg

Datos de dosis

Referencia de laboratorio; no indicado

GHK-Cu

GHK (glycyl-L-histidyl-L-lysine) is an endogenous tripeptide found in human plasma, saliva and urine that binds Cu(II) with high affinity. The GHK-Cu complex is studied as a copper-delivery and signaling molecule: in fibroblast cultures it stimulates collagen and glycosaminoglycan synthesis, modulates metalloproteinases and their inhibitors, and gene-expression analyses associate GHK with shifts in many genes linked to tissue remodeling, antioxidant response and inflammation.

Tesamorelin

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl modification that improves stability against dipeptidyl peptidase-4 cleavage. It binds GHRH receptors on anterior pituitary somatotrophs, activating Gs/cAMP signaling to stimulate pulsatile endogenous growth hormone release, which in turn raises circulating IGF-1.

GHK-Cu

• Increased collagen synthesis in cultured human fibroblasts at nanomolar concentrations (in vitro).
• Enhanced wound contraction, angiogenesis and extracellular-matrix deposition in animal wound models.
• Connectivity Map analyses link GHK to reversal of gene-expression signatures associated with tissue damage and aging.
• Topical cosmetic studies report changes in skin density, elasticity and fine-line measurements.

Tesamorelin

• Reduced visceral adipose tissue (VAT) measured by CT in phase 3 trials in HIV-infected adults with abdominal fat accumulation.
• Increased IGF-1 levels while largely preserving physiological pulsatile GH secretion.
• Reduced hepatic fat fraction in HIV-associated fatty liver studies.
• VAT reductions were not maintained after treatment discontinuation in trial extension phases.

GHK-Cu

• Used as an ingredient in topical cosmetic products; not approved by the FDA as a drug for any indication.
• Most mechanistic evidence is from cell culture and animal models. Human topical research also includes controlled diabetic-ulcer studies; those formulations and wound-care settings do not establish injectable benefits.
• Plasma GHK levels are reported to decline with age, a basis for its study in aging research.

Tesamorelin

• FDA-approved in 2010 (Egrifta) specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.
• Label notes that long-term cardiovascular benefit and safety have not been established, and it is not indicated for weight loss.
• The cited approval does not establish efficacy outside its indication or approve research-market vials.

GHK-Cu

5 referencias · ver

Tesamorelin

4 referencias · ver